Notified Body Delays Pose Market Access Challenges for Medical Device Manufacturers in Europe

Limited notified body capacity is creating bottlenecks for medical device manufacturers seeking European market access, making early regulatory planning increasingly important.

Medical device manufacturers planning to enter the European market continue to face a significant challenge: limited capacity of notified bodies. While the transition to the European medical device regulatory framework has increased the workload involved in conformity assessments, the number of designated bodies has not grown at the same pace. This has contributed to longer waiting periods for manufacturers seeking regulatory approval.

Why ISO 13485 Certification Is Important for Regulatory Planning

ISO 13485 plays a crucial role in medical device quality management. For most manufacturers, establishing a quality management system (QMS) that conforms to ISO 13485 is an essential step towards meeting European regulatory requirements.

Under the European regulatory framework, the quality management system is also assessed as part of the conformity assessment process for most medical device classes. However, obtaining ISO 13485 certification does not automatically grant access to the European market.

The distinction is important for manufacturers planning product launches. Even when a company's quality management system is ready, delays in securing a notified body assessment can extend the overall regulatory timeline.

As a result, manufacturers need to consider notified body availability alongside their ISO 13485 implementation and certification plans.

Early Engagement Can Help Reduce Regulatory Delays

Industry experts recommend that manufacturers approach notified bodies well before completing their quality management systems. Early discussions can help companies understand waiting periods and determine whether a selected body has the capacity to assess their specific device category.

Availability can vary depending on a notified body's designation scope and the device types it is authorised to assess. Manufacturers should therefore confirm that their chosen body is designated for their intended product before committing to a regulatory timeline.

Companies must also recognise that an ISO 13485 certification audit and a regulatory conformity assessment serve different purposes. Although both involve the quality management system, regulatory assessment can require a more detailed review of technical documentation and post-market arrangements.

Building a system that meets the standard is important. Preparing it for regulatory scrutiny is equally necessary.

Manufacturers Urged to Use Waiting Periods Productively

Waiting for a notified body assessment does not have to mean a pause in regulatory preparation. Manufacturers can use this period to strengthen their technical documentation, clinical evaluation and post-market surveillance arrangements.

These activities can help address potential gaps before the formal assessment begins. Better preparation may also reduce the risk of findings that could require additional corrective action and delay market entry.

For companies working towards fixed product launch dates, incorporating notified body waiting periods into project planning can help establish more realistic timelines.

Implications for Indian Medical Device Manufacturers

For Indian manufacturers exporting to Europe, the capacity constraints highlight the need for market-specific regulatory planning.

India's domestic medical device requirements and the European regulatory framework operate under different rules and timelines. Treating ISO 13485 as a single step that automatically enables access to both markets can lead to unrealistic expectations and delays.

A well-developed quality management system can provide a common foundation for meeting requirements across multiple markets. However, manufacturers must separately address the regulatory documentation, assessments and obligations applicable to each destination.

Companies should also verify current European regulatory transition deadlines and notified body availability directly with the relevant authorities and designated bodies. These details are essential for planning certification activities and product launches.

The Way Forward

Limited notified body capacity has made early engagement and realistic scheduling important considerations for medical device manufacturers targeting Europe. ISO 13485 remains a key part of quality management and regulatory readiness, but it should not be treated as a guarantee of immediate market access.

Manufacturers that align quality management system implementation with regulatory planning can better prepare for conformity assessment, manage potential delays and make informed decisions about market entry.